A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins

Cancer Research

Volumn 63, Issue 3, 2003, Pages 593-599

  Marriott, J Blake ^a   Clarke, Ian A ^a   Czajka, Anna ^b   Dredge, Keith ^a   Childs, Kay ^a   Man, Hon Wah ^c   Schafer, Peter ^c   Govinda, Sowmya ^c   Muller, George W ^c   Stirling, David I ^c   Dalgleish, Angus G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 3; CYCLIC AMP; IMMUNOMODULATING AGENT; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN BCL 2; SELECTIVE CYTOKINE INHIBITORY DRUG; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE PHASE; CELL VIABILITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR GROWTH; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASES; CELL CYCLE; CELL DIVISION; COLORECTAL NEOPLASMS; CYCLIC AMP; FEMALE; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; THALIDOMIDE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037308584     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Marriott, J. B., Muller, G., and Dalgleish, A. G. Thalidomide as an emerging immunotherapeutic agent. Immunol. Today, 583: 538-540, 1999.
2. Raje, N., and Anderson, K. Thalidomide - a revival story. N. Engl. J. Med., 341: 1606-1609, 1999.
3. Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., and Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J. Exp. Med., 173: 699-703, 1991.
4. Haslett, P. A., Corral, L. G., Albert, M., and Kaplan, G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med., 187: 1885-1892, 1998.
5. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 91: 4082-4085, 1994.
6. Muller, G. W., Corral, L. G., Shire, M. G., Wang, H., Moreira, A., Kaplan, G., and Stirling, D. I. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J. Med. Chem., 39: 3238-3240, 1996.
7. Corral, L. G., Muller, G. W., Moreira, A. L., Chen, Y., Wu, M., Stirling, D., and Kaplan, G. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor α inhibitory activity. Mol. Med., 2: 506-515, 1996.
8. Corral, L. G., Haslett, P. A., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., and Kaplan, G. Differential cytokine modulation and T cell activation by two distinct classes of Thd analogues that are potent inhibitors of TNF-α. J. Immunol., 163: 380-386, 1999.
9. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y. T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., Muller, G., Stirling, D. I., and Anderson, K. C. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96: 2943-2950, 2000.
10. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J., and Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 341: 1565-1571, 1999.
11. Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M., and Malm, C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br. J. Haematol., 109: 89-96, 2000.
12. Zomas, A., Anagnostopoulos, N., and Dimopoulos, M. A. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplant., 25: 1319-1320, 2000.
13. Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J. J., Chauhan, D., Balinski, K., Zeldis, J., and Anderson, K. C. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 100: 3063-3067, 2002.
14. Eisen, T., Boshoff, C., Mak, I., Sapunar, F., Vaughan, M. M., Pyle, L., Johnston, S. R., Ahem, R., Smith, I. E., and Gore, M. E. Continuous low dose thalidomide: a Phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer, 82: 812-817, 2000.
15. Patt, Y. Z., Hassan, M. M., Lozano, R. D., Ellis, L. M., Peterson, J. A., and Waugh, K. A. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am. J. Clin. Oncol., 23: 319-321, 2000.
16. Gutheil, J., and Finucane, D. Thalidomide therapy in refractory solid tumor patients. Br. J. Haematol., 110: 754, 2000.
17. Marriott, J. B., Westby, M., Cookson, S., Guckian, M., Goodbourn, S., Muller, G., Shire, M. G., Stirling, D., and Dalgleish, A. G. CC-3052: a water soluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production. J. Immunol., 161: 4236-4243, 1998.
18. Muller, G. W., Shire, M. G., Wong, L. M., Corral, L. G., Patterson, R. T., Chen, Y., and Stirling, D. I. Thalidomide analogs and PDE4 inhibition. Bioorg. Med. Chem. Lett., 8: 2669-2674, 1998.
19. Muller, G. W., Chen, R., Huang, S. Y., Corral, L. G., Wong, L. M., Patterson, R. T., Chen, Y., Kaplan, G., Stirling, D. I. Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production. Bioorg. Med. Chem. Lett., 9: 1625-1630, 1999.
20. Guckian, M., Dransfield, I., Hay, P., and Dalgleish, A. G. Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Clin. Exp. Immunol., 121: 472-479, 2000.
21. La Maestra, L., Zaninoni, A., Marriott, J. B., Lazzarin, A., Dalgleish, A. G., and Barcellini, W. The thalidomide analogue CC-3052 inhibits HIV-1 and tumor necrosis factor-α (TNF-α) expression in acutely and chronically infected cells in vitro. Clin. Exp. Immunol., 119: 123-129, 2000.
22. Dredge, K., Marriott, J. B., Macdonald, C. D., Man, H-W., Chen, R., Muller, G. W., Stirling, D., and Dalgleish, A. G. Potent anti-angiogenic activity across distinct classes of domide analogues is independent of immunomodulatory activity. Br. J. Cancer, 87: 1166-1172, 2002.
23. Dredge, K., Marriott, J. B., Todryk, S. M., Muller, G. W., Chen, R., Stirling, D. I., and Dalgleish, A. G. Protective anti-tumor immunity induced by a costimulatory thalidomide analogue in an autologous vaccination model of colorectal cancer is mediated by increased Th1-type immunity. J. Immunol., 168: 4914-4919, 2002.
24. Marriott, J. B., Muller, G. W., Stirling, D., and Dalgleish, A. G. Immunotherapeutic and anti-tumor potential of thalidomide analogues. Exp. Opin. Biol. Ther., 1: 675-682, 2001.
25. Wei, M. C., Zong, W. X., Cheng, E. H., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., and Korsmeyer, S. J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (Wash. DC), 292: 727-730, 2001.
26. Krajewska, M., Moss, S. F., Krajewski, S., Song, K., Holt, P. R., and Reed, J. C. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res., 56: 2422-2427, 1996.
27. Pataer, A., Fang, B., Yu, R., Kagawa, S., Hunt, K. K., McDonnell, T. J., Roth, J. A., and Swisher, S. G. Adenoviral Bak overexpression mediates caspase-dependent tumor killing. Cancer Res., 60: 788-792, 2000.
28. L antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res., 57: 62-67, 1997.